Results 31 to 40 of about 49,757 (329)

Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388. [PDF]

open access: yes, 2020
COR388, a small-molecule lysine-gingipain inhibitor, is currently being investigated in a Phase 2/3 clinical trial for Alzheimer's disease (AD) with exploratory endpoints in periodontal disease.
Arastu-Kapur, Shirin   +10 more
core   +1 more source

An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems

open access: yesPharmaceutics, 2021
Buccal mucosal membrane offers an attractive drug-delivery route to enhance both systemic and local therapy. This review discusses the benefits and drawbacks of buccal drug delivery, anatomical and physiological aspects of oral mucosa, and various in ...
Shery Jacob   +5 more
doaj   +1 more source

Permeability of Buccal Mucosa

open access: yesPharmaceutics, 2021
The buccal mucosa provides an alternative route of drug delivery that can be more beneficial compared to other administration routes. Although numerous studies and reviews have been published on buccal drug delivery, an extensive review of the ...
Apipa Wanasathop   +3 more
doaj   +1 more source

Factors affecting the buccal delivery of deformable nanovesicles based on insulin–phospholipid complex: an in vivo investigation

open access: yesDrug Delivery, 2020
Deformable nanovesicles (DNVs) have been used in the buccal delivery of biomacromolecules due to their ability to enhance drug penetration. However, no breakthroughs have been made until now due to limited understanding of the factors affecting in vivo ...
Yuqi Yang   +6 more
doaj   +1 more source

Use of the Buccal Route for the Administration of an Antiemetic

open access: bronzeAnesthesia & Analgesia, 1992
K. W. Patterson, Padraic W. Keane
openalex   +3 more sources

Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time [PDF]

open access: yesThe Journal of Clinical Pharmacology, 2020
AbstractMidazolam is an established probe drug to assess cytochrome P450 3A activity (phenotyping). Microdosed midazolam is increasingly used for this purpose; a buccal formulation might be of advantage, but buccal absorption might occur. We therefore tested in a single‐center, open‐label clinical trial with 12 healthy volunteers the absolute ...
Jana Grass   +5 more
openaire   +3 more sources

Survey of Provider Preferences Regarding the Route of Misoprostol for Induction of Labor at Term

open access: yesAmerican Journal of Perinatology Reports, 2017
Objective To survey obstetrical provider preferences regarding use of misoprostol for induction of labor (IOL). Methods An anonymous 25-question survey was distributed at an American College of Obstetricians and Gynecologists (ACOG) joint ...
Rachel Towns   +3 more
doaj   +1 more source

The Potential of Films as Transmucosal Drug Delivery Systems

open access: yesPharmaceutics, 2023
Pharmaceutical films are polymeric formulations used as a delivery platform for administration of small and macromolecular drugs for local or systemic action.
Ana Clara Wada de Carvalho   +6 more
doaj   +1 more source

Development of Mucoadhesive Buccal Film for Rizatriptan: In Vitro and In Vivo Evaluation

open access: yesPharmaceutics, 2021
The reduced therapeutic efficacy of rizatriptan in migraine treatment is primarily due to low oral bioavailability and extensive first pass metabolism. The purpose of this investigation was to optimize the thin mucoadhesive buccal film of rizatriptan and
Anroop B. Nair   +6 more
doaj   +1 more source

The administration of multipotent stromal cells at precancerous stage precludes tumor growth and epithelial dedifferentiation of oral squamous cell carcinoma [PDF]

open access: yes, 2017
Multipotent stromal cells (MSCs) are envisioned as a powerful therapeutic tool. As they home into tumors, secrete trophic and vasculogenic factors, and suppress immune response their role in carcinogenesis is a matter of controversy.
Arango Rodríguez, Martha   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy